International pricing policy shifts are on TLV’s radar.
TLV has issued an interim update on its government mandate to analyse how Sweden’s pharmaceutical pricing system could be influenced by developments in the international market, with a specific focus on the US “most favoured nation” (MFN) policy.
TLV says it remains unclear how the US’s new pricing models will be implemented and what their consequences could be for medicine prices and availability. According to TLV, the implementation has not yet produced clear effects on the Swedish pharmaceutical market, and it is still too early to say what measures may be needed.
What TLV is doing now
- monitoring and analysing US policy and implementation of MFN, and potential effects on Sweden
- developing methods to assess access to and use of new medicines (subsidised and non-subsidised), including comparisons with other countries
- mapping which medicines are not subsidised via Sweden’s national process
- preparing a mapping of confidential agreements in European countries
TLV will hold four seminars this year and continue interviews and international information exchange. Final reporting is due by 1 december 2026. Read more at https://www.tlv.se/press/nyheter/arkiv/2026-04-01-tlv-foljer-noga-utvecklingen-pa-den-internationella-lakemedelsmarknaden.html
